Article Text

AB0531 Prevalence and differences of the metabolic syndrome in patients with psoriatic arthritis and ankylosing spondylitis
  1. D. Nemes1,2,
  2. E. Amaricai1,
  3. L. Catan1,
  4. M. Dragoi1,2,
  5. D. Popa1,2,
  6. G. Puenea1,
  7. D. Andrei1,
  8. R. Balacescu2
  1. 1Medical Rehabilitation, “Victor Babes” University of Medicine and Pharmacy
  2. 2Rehabilitation and rheumatology, City University and Emergency Hospital, Timisoara, Romania


Background Metabolic syndrome (MetS) is regarded as one of the extra articular manifestations of psoriasis and psoriatic arthritis (PsA). On the other hand, the data about the MetS prevalence in ankylosing spondylitis (AS) are limited.

Objectives To evaluate the differences of MetS in patients with psoriatic arthritis and ankylosing spondylitis and to study the possible relationship of MetS with inflammation biomarkers and patients’ functional status.

Methods The study was conducted on 115 AS patients and 103 PsA patients. The patients were investigated for MetS according to the National Cholesterol Education Program. Data regarding MetS (triglycerides, HDL cholesterol, fasting glucose, blood pressure and waist circumference) and inflammatory status (ESR, CRP) were recorded. The general health was evaluated by the Health Assessment Questionnaire (HAQ).

Results The prevalence of MetS was significantly higher in PsA (34%) than in AS (14%) (p<0.001).

Conclusions No significant differences of MetS parameters were noticed between PsA and AS patients. Instead, there were recorded statistically significant differences of inflammatory biomarkers and health status. The patients with AS and MetS had a higher inflammatory activity and a decreased quality of life in comparison with the patients with PsA and MetS.

References Mok CC, Ko GT, Ho LY, Yu KL. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res 2011;63(2):195-202

Tobin AM, Veale DJ, Fitzgerald O. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010;37(7):1386-94

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.